that capacity, he receives a stipend (starting April 11, 2018) and was awarded unexercised stock options (effective April 23, 2018) but owns no stock. My current disclosures as of this writing also include Unum Therapeutics and Bain Capital. All of these relationships are included in the disclosure statement below.

I have requested that these articles be amended online to include these disclosures. I appreciate the opportunity to provide these amendments and explain to the readers and editors of JAMA Oncology my previous and current disclosures.

Charles S. Fuchs, MD, MPH

Author Affiliation: Yale Cancer Center, New Haven, Connecticut.

Corresponding Author: Charles S. Fuchs, MD, MPH, Yale Cancer Center, 333 Cedar St, New Haven, CT 06510 (charles.fuchs@yale.edu).

Published Online: March 7, 2019. doi:10.1001/jamaoncol.2019.0235

Conflict of Interest Disclosures: Dr Fuchs has been a consultant and/or a scientific advisor for Eli Lilly, Emergent Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharmaceuticals, Unum Therapeutics, Dicerna, Bayer, Celgene, Agios, Gilead Sciences, Bain Capital, Five Prime Therapeutics, Taiho, and KEW. Dr Fuchs also serves on the Board of Directors for CytoriX Therapeutics; in that capacity, he receives a stipend (starting April 11, 2018) and was awarded unexercised stock options (effective April 23, 2018) but owns no stock.